Israel Englander Amylyx Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 3,081,853 shares of AMLX stock, worth $15.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,081,853

Previous 594,236 418.62%

Holding current value

$15.1 Million

Previous $2.24 Million 387.01%

% of portfolio

0.01%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$3.0 - $4.15 $7.46 Million - $10.3 Million	2,487,617 Added 418.62%	3,081,853 $10.9 Million
Q4 2024 Feb 14, 2025	BUY	$2.94 - $7.03 $404,014 - $966,062	137,420 Added 30.08%	594,236 $2.24 Million
Q3 2024 Nov 14, 2024	SELL	$1.65 - $3.24 $1.78 Million - $3.49 Million	-1,078,362 Reduced 70.24%	456,816 $1.48 Million
Q2 2024 Aug 14, 2024	SELL	$1.62 - $2.71 $1.52 Million - $2.54 Million	-936,277 Reduced 37.88%	1,535,178 $2.92 Million
Q1 2024 May 15, 2024	BUY	$2.71 - $19.57 $538,780 - $3.89 Million	198,812 Added 8.75%	2,471,455 $7.02 Million
Q4 2023 Feb 14, 2024	BUY	$12.07 - $18.46 $4.24 Million - $6.48 Million	351,012 Added 18.27%	2,272,643 $33.5 Million
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $17.8 Million - $26.6 Million	847,021 Added 78.82%	1,921,631 $41.4 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $5.96 Million - $8.81 Million	215,195 Added 25.04%	1,074,610 $31.5 Million
Q4 2022 Feb 14, 2023	SELL	$29.75 - $39.26 $1.84 Million - $2.42 Million	-61,713 Reduced 6.7%	859,415 $31.8 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $8.15 Million - $14.7 Million	475,084 Added 106.51%	921,128 $25.9 Million

Others Institutions Holding AMLX

# of Institutions

148

Shares Held

73M

Call Options Held

148K

Put Options Held

98.7K

View Full List

About Amylyx Pharmaceuticals, Inc.

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $287M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

More about AMLX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account